Indaptus enters $100M ATM equity offering agreement with H.C. Wainwright

Indaptus Therapeutics, Inc.

Amended and restated ATM agreement executed Aug 28, 2026, replacing June 1, 2022 pact with H.C. Wainwright.
Company may sell up to $100M in common stock through Wainwright as sales agent or principal.
Placement fee of 3.0% of gross sales proceeds for agent sales; no obligation to sell any shares.
Prospectus supplement filed Aug 31, 2026, amended Sept 4, 2026 to update dilution disclosure.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.